Risk or Protective Factors of Prostate Cancer Progressing to Castration Resistant Prostate Cancer After Androgen Deprivation Therapy
Objective To screen the possible risk factors and protective factors for prostate cancer early (in 2 years)progressing to castration resistant prostate cancer (CRPC). Methods A total of 71 patients who had progressed to CRPC in 2 years were classified as case group and 71 patients without progressin...
Main Authors: | CHEN Chiwei, LIN Mandi, LIU Hao, ZHU Lujun, ZENG Haiping, WANG Zhigang, WANG Jun, CHEN Ming |
---|---|
Format: | Article |
Language: | zho |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2020-07-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Subjects: | |
Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2020.19.1440.htm |
Similar Items
-
Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
by: Lixin Mai, et al.
Published: (2020-12-01) -
The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01) -
Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
by: Daisuke Obinata, et al.
Published: (2020-10-01) -
Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy
by: Minyong Kang, et al.
Published: (2015-12-01) -
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
by: Mark N Stein, et al.
Published: (2014-06-01)